New Study Demonstrating the Selectivity of Progenra, Inc.'s Novel Anti-Tumor Compound  
11/28/2011 10:09:26 AM

OXFORD, England & MALVERN, Pa.--(BUSINESS WIRE)--Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled “Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes” (Altun et al, Chemistry & Biology, Volume 18, Issue 11, 1401-1412, 23 November 2011) that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs). The new method utilizes LC-MS-MS to detect DUBs labeled with DUB active site inhibitors and was tested to confirm the inhibitory profile of two small molecule inhibitors, PR-619 and P022077. Data presented in the publication confirm the selective inhibition of USP7 in human cells treated with P022077, in contrast to the pan-DUB inhibition profile of the tool compound PR-619 in the same cells.